ReviewCurrent rheumatology reports2026
Therapeutics in Axial Spondyloarthritis: A Review of What Works - SPARTAN 2026 Annual Meeting Proceedings.
Review in Current rheumatology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewAxial spondyloarthritis (axSpA) encompasses a broad disease spectrum, and the management landscape has expanded considerably over the past two decades. This review synthesizes the current evidence on pharmacological and non-pharmacological interventions in axSpA, addressing both symptom control and radiographic outcomes across drug classes and patient contexts. RECENT
findingsNSAIDs remain the cornerstone of first-line therapy, with emerging long-term cohort data suggesting a dose-response relationship between NSAID exposure and reduced radiographic spinal progression in radiographic disease. TNF inhibitors retain the most mature evidence base regarding radiographic progression, with longitudinal data associating TNFi exposure with slower mSASSS progression and suggesting that this effect may be partially uncoupled from inflammation as measured by ASDAS, particularly with earlier treatment initiation. IL-17 inhibitors demonstrate robust symptomatic efficacy, while two-year structural data show low radiographic progression, although a treatment-specific structural effect has not been established. JAK inhibitors provide effective symptom control, and longer-term radiographic data are now available, but controlled evidence demonstrating inhibition of structural progression remains lacking. Exercise therapy, supported by a recent systematic review and meta-analysis, improves disease activity, function, mobility, pain, and fatigue, with subgroup analyses showing significant BASFI improvement only for sessions lasting ≤60 minutes. Obesity is associated with greater disease activity and poorer response to TNF inhibitors. Symptom control is achievable across all major drug classes in axSpA. Evidence regarding radiographic progression is most mature for TNF inhibitors, more limited for IL-17 inhibitors, context-dependent for NSAIDs, and currently insufficient to establish structural modification with JAK inhibitors. Effective management requires integrating pharmacological and non-pharmacological strategies, including structured exercise as an evidence-based intervention, while recognizing obesity as a clinically relevant prognostic factor.
Indexed as
Identifiers
42828651What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.